过去一年中添加的文章，按日期排序
Successful treatment with belantamab mafodotin in a heavily pretreated patient with multiple myeloma and liver extramedullary disease
N Sgherza, P Curci, G Di Carlo, D Grande… - Leukemia & …, 2024 - Taylor & Francis
19 天前 - … and dexamethasone versus daratumumab, bortezomib and dexamethasone after at
least … pomalidomide and dexamethasone is compared with bortezomib, pomalidomide and …
least … pomalidomide and dexamethasone is compared with bortezomib, pomalidomide and …
[HTML][HTML] Extended DaraKRd: Are we enhancing outcomes by prolonging treatment?
TM Schmidt - Blood Cancer Journal, 2024 - nature.com
24 天前 - … daratumumab to Rd was shown to have a profound PFS benefit among unfit and
frail patients … isatuximab-carfilzomib-lenalidomide-dexamethasone vs carfilzomib-lenalidomide-…
frail patients … isatuximab-carfilzomib-lenalidomide-dexamethasone vs carfilzomib-lenalidomide-…
EE496 Cost of Anti-CD38 Monoclonal Antibodies in Combination With Carfilzomib and Dexamethasone for Relapsed Refractory Multiple Myeloma
P Lin, A Petitjean, E Drea, F Lin - Value in Health, 2024 - valueinhealthjournal.com
27 天前 - … (Isa) and daratumumab (Dara), in combination with carfilzomib (K) and
dexamethasone (d), have provided important treatment options for patients with relapsed refractory …
dexamethasone (d), have provided important treatment options for patients with relapsed refractory …
Carfilzomib and Proteinuria: Potential Interference or Iatrogeny?
L Vaudran, F Loiseleur, N Nezry… - The Journal of …, 2024 - academic.oup.com
29 天前 - … of carfilzomib, daratumumab, and dexamethasone as second line therapy for a
refractory multiple myeloma. The patient’s … profile from several patients receiving carfilzomib. The …
refractory multiple myeloma. The patient’s … profile from several patients receiving carfilzomib. The …
Novel chemotherapy combination of carfilzomib with dexamethasone, cyclophosphamide, etoposide and cisplatin (K-DCEP) for the treatment of relapsed/refractory …
CB Wagner, K Julian, B Bryan, MN Steinbach… - Leukemia & …, 2024 - Taylor & Francis
30 天前 - … Of the triple-class refractory patients, all were refractory to daratumumab, bortezomib,
… Two patients had been exposed to K previously but were not refractory to K. All patients …
… Two patients had been exposed to K previously but were not refractory to K. All patients …
Efficacy of carfilzomib-based regimens as induction/consolidation therapy in newly diagnosed multiple myeloma: A meta-analysis.
30 天前 - … on PubMed and Embase with keywords for “Carfilzomib” and “multiple myeloma” till
1/1/… were 90% and 7%, respectively in patients with K and dexamethasone (d). In one trial (…
1/1/… were 90% and 7%, respectively in patients with K and dexamethasone (d). In one trial (…
[HTML][HTML] The lymphocyte/monocyte ratio predicts the efficacy of isatuximab plus pomalidomide in multiple myeloma patients
Y Shimazu, J Kanda, Y Onda, S Fuchida, K Ohta… - Cancer Immunology …, 2024 - Springer
42 天前 - … , carfilzomib and dexamethasone [3,4,5]. … of daratumumab had a negative impact
on prognosis after the Isa-PD regimen, we analyzed the interval between last daratumumab …
on prognosis after the Isa-PD regimen, we analyzed the interval between last daratumumab …
How can we stamp out high-risk myeloma?
R Banerjee, JR Mikhael - Blood, 2024 - ashpublications.org
43 天前 - … patients with high-risk (HR) multiple myeloma (MM). Induction therapy included
6 cycles of … therapy with daratumumab, carfilzomib, lenalidomide, and dexamethasone (D-KRd), …
6 cycles of … therapy with daratumumab, carfilzomib, lenalidomide, and dexamethasone (D-KRd), …
A Look at Genomic & Immune Signatures in Multiple Myeloma
DK Das - Oncology Times, 2024 - journals.lww.com
62 天前 - … impacting clinical outcomes in patients undergoing daratumumab-based therapies.
… therapy with daratumumab, carfilzomib, lenalidomide, and dexamethasone. For example, …
… therapy with daratumumab, carfilzomib, lenalidomide, and dexamethasone. For example, …
[HTML][HTML] Cross-Trial Comparison Analyses in R/R Multiple Myeloma
TR Collins - 2024 - ashpublications.org
64 天前 - … -free survival (PFS) for the carfilzomib-dexamethasone-daratumumab (KdD) triplet
than … -bortezomib-dexamethasone (PVd) or daratumumab-pomalidomide-dexamethasone (…
than … -bortezomib-dexamethasone (PVd) or daratumumab-pomalidomide-dexamethasone (…